Nizatidine ameliorates gastroparesis in Parkinson's disease: a pilot study.
Mov Disord
; 29(4): 562-6, 2014 Apr.
Article
en En
| MEDLINE
| ID: mdl-24375669
ABSTRACT
BACKGROUND:
The objective of this work was to perform an open trial of the effects of nizatidine (NZT), a selective histamine H2-receptor antagonist and a cholinomimetic, on gastroparesis in Parkinson's disease (PD) patients, using objective parameters given by a gastric emptying study using a (13) C-sodium acetate expiration breath test.METHODS:
Twenty patients with PD were enrolled in the study. There were 13 men and 7 women; aged 68.0 ± 7.72 years; disease duration 5.50 ± 3.62 years. All patients underwent the breath test and a gastrointestinal questionnaire before and after 3 months of administration of NZT at 300 mg/day. Statistical analysis was performed by Student t test.RESULTS:
NZT was well tolerated by all patients and none had abdominal pain or other adverse effects. NZT significantly shortened Tmax ((13) C) (the peak time of the (13) C-dose-excess curve) (P < 0.05).CONCLUSIONS:
Although this is a pilot study, we found a significant shortening of gastric emptying time after administration of NZT in PD patients.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Enfermedad de Parkinson
/
Nizatidina
/
Gastroparesia
/
Antagonistas de los Receptores H2 de la Histamina
Tipo de estudio:
Etiology_studies
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Mov Disord
Asunto de la revista:
NEUROLOGIA
Año:
2014
Tipo del documento:
Article
País de afiliación:
Japón